Cortecs Post-Macritonin Lead Pipeline Candidate Will Be Macrulin
Executive Summary
Cortecs is shifting its clinical focus to the oral insulin formulation Macrulin and the oral mucosal vaccine Pseudostat following its decision to discontinue development of its osteoporosis treatment Macritonin (oral salmon calcitonin), the firm announced May 25.